Clinical Trial

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

Study acronym: ATTAIN-OA PAIN
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks.
Trial Details
NCT Number NCT07153471
Lead Sponsor Eli Lilly and Company
Conditions Osteoarthritis
Enrollment 800 participants
Start Date 2025-09-15
Primary Completion 2028-04 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-17